LT2882716T - Neprilizino inhibitoriai - Google Patents
Neprilizino inhibitoriaiInfo
- Publication number
- LT2882716T LT2882716T LTEP13750454.4T LT13750454T LT2882716T LT 2882716 T LT2882716 T LT 2882716T LT 13750454 T LT13750454 T LT 13750454T LT 2882716 T LT2882716 T LT 2882716T
- Authority
- LT
- Lithuania
- Prior art keywords
- neprilysin inhibitors
- neprilysin
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680804P | 2012-08-08 | 2012-08-08 | |
| US201361774163P | 2013-03-07 | 2013-03-07 | |
| PCT/US2013/053956 WO2014025891A1 (en) | 2012-08-08 | 2013-08-07 | Neprilysin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2882716T true LT2882716T (lt) | 2017-02-10 |
Family
ID=48998730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13750454.4T LT2882716T (lt) | 2012-08-08 | 2013-08-07 | Neprilizino inhibitoriai |
Country Status (32)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ611528A (en) | 2010-12-15 | 2015-06-26 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
| US8586536B2 (en) | 2010-12-15 | 2013-11-19 | Theravance, Inc. | Neprilysin inhibitors |
| US8449890B2 (en) | 2011-02-17 | 2013-05-28 | Theravance, Inc. | Neprilysin inhibitors |
| CA2825737C (en) | 2011-02-17 | 2018-11-13 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
| US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| AR089955A1 (es) * | 2012-02-15 | 2014-10-01 | Theravance Inc | Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico |
| EP2858650B1 (en) | 2012-06-08 | 2018-11-14 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| AU2013299642B2 (en) | 2012-08-08 | 2017-06-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| EP2964616B1 (en) | 2013-03-05 | 2017-05-03 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| EP3099678B1 (en) | 2014-01-30 | 2018-12-12 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| US9585882B2 (en) * | 2014-01-30 | 2017-03-07 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| WO2016086798A1 (zh) * | 2014-12-03 | 2016-06-09 | 上海翰森生物医药科技有限公司 | Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用 |
| ES2923002T3 (es) | 2015-02-11 | 2022-09-22 | Theravance Biopharma R&D Ip Llc | Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina |
| RU2715241C2 (ru) | 2015-02-19 | 2020-02-26 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота |
| PT3408260T (pt) * | 2016-03-08 | 2021-07-23 | Theravance Biopharma R&D Ip Llc | Ácido (2s,4r)-5-(5¿-cloro-2¿-fluoro-[1,1¿-bifenil]-4-il)-2- (etoximetil)-4-(3-hidroxi-isoxazole-5-carboxamido)-2- metilpentanoico cristalino e suas utilizações |
| CN105753741A (zh) * | 2016-04-26 | 2016-07-13 | 常州制药厂有限公司 | 一种抗心衰药物Sacubitril中间体的制备方法 |
| CN107903191A (zh) * | 2017-12-04 | 2018-04-13 | 武汉药明康德新药开发有限公司 | 2‑NH‑Boc‑3‑(3`,4`‑二甲基‑[1,1`‑联苯]‑4)丙酸的制法 |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物 |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| RU2736511C1 (ru) * | 2020-01-24 | 2020-11-17 | Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" | Производные бифенила, обладающие биологической активностью, фармацевтические композиции и способы лечения на основе этих соединений и их применение |
| TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
| KR102485499B1 (ko) * | 2022-07-15 | 2023-01-09 | 오가노이드사이언스 주식회사 | 신장 질환의 치료 또는 예방용 조성물 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
| EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| KR880007441A (ko) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JPH11505522A (ja) | 1995-04-21 | 1999-05-21 | ノバルティス・アクチエンゲゼルシャフト | エンドセリン阻害剤としてのｎ−アロイルアミノ酸アミド |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| RU2530900C2 (ru) | 2007-01-12 | 2014-10-20 | Новартис Аг | Способ получения 5-бифенил-4-амино-2-метилпентановой кислоты |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| PE20091364A1 (es) | 2008-01-17 | 2009-10-13 | Novartis Ag | Proceso para la preparacion de inhibidores de nep |
| SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| JP5420761B2 (ja) * | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| JP5447204B2 (ja) * | 2009-06-15 | 2014-03-19 | 東洋インキＳｃホールディングス株式会社 | （メタ）アクリロイル基を有するウレタン樹脂及び該ウレタン樹脂を含有する活性エネルギー線硬化性接着剤、並びに太陽電池用裏面保護シート |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| SI2526088T1 (sl) | 2010-01-22 | 2015-12-31 | Novartis Ag | Intermediati nevtralnih endopeptidaznih inhibitorjev in metoda za njihovo pripravo |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
| NZ611528A (en) | 2010-12-15 | 2015-06-26 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
| US8586536B2 (en) | 2010-12-15 | 2013-11-19 | Theravance, Inc. | Neprilysin inhibitors |
| CA2825737C (en) | 2011-02-17 | 2018-11-13 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
| US8449890B2 (en) | 2011-02-17 | 2013-05-28 | Theravance, Inc. | Neprilysin inhibitors |
| WO2012166389A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| CA2835220A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| AR089955A1 (es) * | 2012-02-15 | 2014-10-01 | Theravance Inc | Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico |
| US9045443B2 (en) | 2012-05-31 | 2015-06-02 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
| EP2858650B1 (en) | 2012-06-08 | 2018-11-14 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| JP6162230B2 (ja) | 2012-06-08 | 2017-07-12 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ネプリライシン阻害剤 |
| AU2013299642B2 (en) | 2012-08-08 | 2017-06-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| EP3099678B1 (en) | 2014-01-30 | 2018-12-12 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
-
2013
- 2013-08-07 AU AU2013299642A patent/AU2013299642B2/en active Active
- 2013-08-07 HU HUE13750454A patent/HUE031301T2/hu unknown
- 2013-08-07 PT PT137504544T patent/PT2882716T/pt unknown
- 2013-08-07 SG SG11201500845UA patent/SG11201500845UA/en unknown
- 2013-08-07 SM SM20170134T patent/SMT201700134T1/it unknown
- 2013-08-07 ME MEP-2017-51A patent/ME02626B/me unknown
- 2013-08-07 MX MX2015001711A patent/MX366149B/es active IP Right Grant
- 2013-08-07 SI SI201330556A patent/SI2882716T1/sl unknown
- 2013-08-07 KR KR1020157003174A patent/KR102104954B1/ko active Active
- 2013-08-07 HR HRP20170088TT patent/HRP20170088T1/hr unknown
- 2013-08-07 ES ES13750454.4T patent/ES2615275T3/es active Active
- 2013-08-07 BR BR112015002821-7A patent/BR112015002821B1/pt active IP Right Grant
- 2013-08-07 PL PL13750454T patent/PL2882716T3/pl unknown
- 2013-08-07 AR ARP130102816A patent/AR092073A1/es not_active Application Discontinuation
- 2013-08-07 US US13/961,269 patent/US9126956B2/en active Active
- 2013-08-07 NZ NZ704741A patent/NZ704741A/en not_active IP Right Cessation
- 2013-08-07 DK DK13750454.4T patent/DK2882716T3/en active
- 2013-08-07 MY MYPI2015000065A patent/MY172924A/en unknown
- 2013-08-07 RS RS20170240A patent/RS55797B1/sr unknown
- 2013-08-07 EP EP13750454.4A patent/EP2882716B9/en active Active
- 2013-08-07 RU RU2015107751A patent/RU2650114C2/ru active
- 2013-08-07 JP JP2015526672A patent/JP6092390B2/ja active Active
- 2013-08-07 CN CN201380042178.6A patent/CN104520277B/zh active Active
- 2013-08-07 CA CA2879697A patent/CA2879697C/en active Active
- 2013-08-07 WO PCT/US2013/053956 patent/WO2014025891A1/en not_active Ceased
- 2013-08-07 LT LTEP13750454.4T patent/LT2882716T/lt unknown
- 2013-08-08 TW TW102128546A patent/TWI603958B/zh active
-
2015
- 2015-01-13 IL IL236698A patent/IL236698A/en active IP Right Grant
- 2015-01-27 CO CO15016031A patent/CO7180201A2/es unknown
- 2015-01-28 ZA ZA2015/00654A patent/ZA201500654B/en unknown
- 2015-02-06 PH PH12015500260A patent/PH12015500260A1/en unknown
- 2015-07-29 US US14/812,095 patent/US9670186B2/en active Active
-
2017
- 2017-02-08 JP JP2017020923A patent/JP2017105817A/ja not_active Withdrawn
- 2017-02-24 CY CY20171100263T patent/CY1118681T1/el unknown
- 2017-04-26 US US15/497,508 patent/US9873685B2/en active Active
- 2017-10-23 IL IL255206A patent/IL255206A0/en active IP Right Grant
- 2017-12-14 US US15/841,749 patent/US10189823B2/en active Active
-
2018
- 2018-12-04 US US16/209,112 patent/US10570120B2/en active Active
-
2020
- 2020-01-10 US US16/739,525 patent/US11124502B2/en active Active
-
2021
- 2021-08-16 US US17/445,096 patent/US11634413B2/en active Active
-
2023
- 2023-02-23 US US18/173,573 patent/US11919888B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255206A0 (en) | Inhibitors of neprilysin | |
| ZA201408634B (en) | Neprilysin inhibitors | |
| TWI560172B (en) | Neprilysin inhibitors | |
| ZA201407554B (en) | Dna-pk inhibitors | |
| IL226327A0 (en) | Naphrelysin inhibitors | |
| IL226451A0 (en) | Naphrelysin inhibitors | |
| LT2964616T (lt) | Neprilizino inhibitoriai | |
| PT2912021T (pt) | Inibidores de agrecanase | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| GB201223308D0 (en) | Enzyme inhibitors | |
| GB201220824D0 (en) | Ecosocket |